Patents Assigned to C4 Therapeutics, Inc.
-
Publication number: 20240245677Abstract: Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: March 8, 2024Publication date: July 25, 2024Applicant: C4 THERAPEUTICS, INC.Inventors: Katrina L. Jackson, Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap, Minsheng He, Robert T. Yu, Matthew J. Schnaderbeck, Kathleen Neville, Siyi Jiang, Meiqi Li, Qianwei Liu, Manjie Zheng, Jia Li, Liwei Zhang
-
Publication number: 20240199581Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.Type: ApplicationFiled: December 8, 2023Publication date: June 20, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveshuk, Katrina L. Jackson, Yanke Liang, Robert T. Yu, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Morgan Welzel O'Shea, Gesine Kerstin Veits, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Franceso Tommaso Pettazzoni, Juergen Wichmann
-
Publication number: 20240199638Abstract: The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: ApplicationFiled: October 30, 2023Publication date: June 20, 2024Applicant: C4 Therapeutics, Inc.Inventors: Roger Norcross, Annick Goergler, Philipp Schmid, Fabian Dey, Eric Andre Kusznir
-
Patent number: 11992531Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: November 30, 2020Date of Patent: May 28, 2024Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
-
Publication number: 20240158418Abstract: The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.Type: ApplicationFiled: November 21, 2023Publication date: May 16, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
-
Publication number: 20240109889Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: ApplicationFiled: September 19, 2023Publication date: April 4, 2024Applicant: C4 Therapeutics, Inc.Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
-
Publication number: 20240076300Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.Type: ApplicationFiled: May 8, 2023Publication date: March 7, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
-
Publication number: 20240051953Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: October 13, 2022Publication date: February 15, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Publication number: 20240018156Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.Type: ApplicationFiled: March 6, 2023Publication date: January 18, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
-
Publication number: 20230416251Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.Type: ApplicationFiled: January 24, 2023Publication date: December 28, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
-
Publication number: 20230372496Abstract: Heterobifunctional compounds for targeted protein degradation that include a tricyclic cereblon binder linked to an appropriate protein targeting ligand to degrade a targeted disease-mediating protein of interest are provided.Type: ApplicationFiled: April 14, 2023Publication date: November 23, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Corey Don Anderson, James A. Henderson, Victoria Garza, Yanke Liang, Moses Moustakim, Katrina L. Jackson, Martin Duplessis
-
Publication number: 20230357180Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.Type: ApplicationFiled: December 12, 2022Publication date: November 9, 2023Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
-
Patent number: 11802131Abstract: The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: GrantFiled: March 4, 2020Date of Patent: October 31, 2023Assignee: C4 Therapeutics, Inc.Inventors: Roger Norcross, Annick Goergler, Philipp Schmid, Fabian Dey, Eric Andre Kusznir
-
Publication number: 20230339902Abstract: Tricyclic compounds that degrade IKZF2 and/or IKZF4 are provided for medical therapy, including abnormal cellular proliferation, including cancer, inflammatory disorders, neurodegenerative disorders or autoimmune disorders.Type: ApplicationFiled: April 14, 2023Publication date: October 26, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, James A. Henderson, Moses Moustakim, Andrew Charies Good, David Prola
-
Patent number: 11787802Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: GrantFiled: January 14, 2022Date of Patent: October 17, 2023Assignee: C4 Therapeutics, Inc.Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
-
Patent number: 11753397Abstract: The invention provides cereblon binders of Formulas: or pharmaceutically acceptable salts thereof, for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications to treat medical disorders including, but not limited to cancer.Type: GrantFiled: September 24, 2020Date of Patent: September 12, 2023Assignee: C4 Therapeutics, Inc.Inventors: James A. Henderson, Gesine Kerstin Veits, Minsheng He, Christopher G. Nasveschuk, Andrew J. Phillips, Andrew Charles Good
-
Publication number: 20230279023Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: October 3, 2022Publication date: September 7, 2023Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
-
Publication number: 20230233692Abstract: Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.Type: ApplicationFiled: February 3, 2023Publication date: July 27, 2023Applicant: C4 Therapeutics, Inc.Inventors: James A. Henderson, Christopher G. Naveschuk, Kiel Lazarski, Victoria Garza, Moses Moustakim, Jae Young Ahn, Gesine Kerstin Veits, Morgan Welzel O'Shea, Ryan E. Michael, Jeremy L. Yap, Yanke Liang, Andrew Charles Good, Mark E. Fitzgerald, Robert T. Yu
-
Patent number: 11691972Abstract: A BRD9 protein degrading compound of structure or a pharmaceutically acceptable salt thereof is provided for the treatment of a disorder mediated by BRD9, including but not limited to abnormal cellular proliferation including cancer.Type: GrantFiled: December 2, 2021Date of Patent: July 4, 2023Assignee: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Publication number: 20230192643Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: ApplicationFiled: August 1, 2022Publication date: June 22, 2023Applicant: C4 Therapeutics, Inc.Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
